Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Publication Type:
Journal Article
Authors:
Alonso, S.;
Riveiro-Barciela, M.;
Fernández, I.;
Rincón, D.;
Real, Y.;
Llerena, S.;
Gea, F.;
Olveira, A.;
Fernandez-Carrillo, C.;
Polo, B.;
Carrión, J. A.;
Gómez, A.;
Devesa, M. J.;
Baliellas, C.;
Castro, Á;
Ampuero, J.;
Granados, R.;
Pascasio, J. M.;
Rubín, A.;
Salmeron, J.;
Badia, E.;
Planas, J. M. M.;
Lens, S.;
Turnes, J.;
Montero, J. L.;
Buti, M.;
Esteban, R.;
Fernández-Rodríguez, C. M.Source:
J Viral Hepat, Volume 24, Issue 4, p.304 - 311 (2017)
Keywords:
Cirrhosis,
daclatasvir,
genotype 3,
Hepatitis C,
ledipasvir,
observational study,
real-world cohort,
sofosbuvir,
SVR12
